Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6447MR)

This product GTTS-WQ6447MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6447MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12834MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ12644MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ4492MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ3185MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ6413MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ14384MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ2892MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ3403MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW